newsfilter
← Latest News
Business Wire·

First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)

Earlier studies have shown the granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing effect of lenzilumab may benefit CMML patients with RAS pathway mutations Study is intended to build on evidence that certain CMML patients have